ビバリルジン
順序:D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH
エイリアス:126:PN:WO2004076484ページ:31 主張されたタンパク質;アンジオマックス;BG 8967;ビバリルジン;ヒルログ; ヒルログ 1
Cas No.: 128270-60-0
分子式: C98H138N24O33
分子量: 2180.29
純度 (HPLC): 98.0%分.
外観: 白い粉
単一の不純物 (HPLC): 1.0%最大
アミノ酸組成: 理論値の±10%
ペプチド含有量 (N%): >80.0%
含水量 (カール・フィッシャー): <8.0%
トリフルオロアセテート含有量(HPIC): >12.0%
MS (ESI): 一貫性のある
マスバランス: 95.0~105.0%
学年 : 医薬品グレード
保管所: 閉まっている, 下 2 ～8℃保存
使用法 : この製品は、主に不安定狭心症の治療における血管形成の予防に使用されます。, 前後の虚血性合併症。循環トロンビンと血栓結合トロンビンの両方を阻害します。, トロンビンを介した血小板の活性化と凝集を阻害しながら.
ビバリルジン (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, トロンビンを介した血小板の活性化と凝集を阻害しながら. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.
Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials
Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).
Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.
Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.
